Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
86
States / cities
Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
Conditions
Femoracetabular Impingement, Hip Arthroscopy
Interventions
Ketorolac, Control (Standard treatment), Omeprazole
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Landau-Kleffner Syndrome, Status Epilepticus, Electrographic
Interventions
Diazepam, Acetazolamide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Alcohol Withdrawal
Interventions
Lorazepam, Diazepam
Drug
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Conditions
Acupuncture, Pain, Postoperative, Vasectomy
Interventions
Acupuncture, Standardized pre-procedure medications
Procedure · Other
Lead sponsor
Matthew Snyder
Federal
Eligibility
25 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Completed Phase 3 Interventional Results available

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

NCT02721069
Conditions
Acute Repetitive Seizures, Breakthrough Seizures
Interventions
NRL-1
Drug
Lead sponsor
Neurelis, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Little Rock, Arkansas • Rochester, Minnesota • St Louis, Missouri + 2 more
Conditions
Acute Repetitive Seizures
Interventions
NRL-1
Drug
Lead sponsor
Neurelis, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Conditions
Epilepsy
Interventions
Diazepam Buccal Film, Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Winter Park, Florida
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg, diazepam 20 mg, placebo
Drug · Other
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah